glp 1 drugs non injectable New GLP-1 Guidelines for Type 2 Diabetes in 2025 Most obesity drugs do not

Protocol for a randomised, double-blinded, placebo-controlled, double-dummy 6-week clinical trial comparing the treatment effects of the glucagon-like peptide 1 receptor agonist liraglutide versus the bile acid sequestrant colesevelam on bile acid malabsorption

doi: 10.1002/dmrr.70029 25 MilaniIGuariscoGChinucciMGaitaCLeonettiFCapocciaD

48 Similar results were obtained in a hGLP-1R knock-in murine model in which the administration of Danuglipron resulted in an overall improvement of glucose tolerance and food intake reduction, thus opening the possibility to use an effective oral GLP-1RA

First: plan for long-term, possibly lifelong therapy

Employers can stay ahead of the GLP-1 curve by proactively evaluating coverage strategies and vendors, monitoring utilization trends, and leveraging data-driven insights to manage costs effectively in 2025 and beyond.

Claims of disease reversal or cure remain speculative